Source 1primary paper2023ACS Nano
Toolkit/NanoLuc-modified macrophage membranes
NanoLuc-modified macrophage membranes
Also known as: luciferase NanoLuc-modified macrophage membranes
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
NanoLuc-modified macrophage membranes are a membrane-camouflage delivery harness used on nanoparticles for in situ bioluminescence-driven optogenetic therapy of retinoblastoma. The reported construct was combined with folic acid ligands and supported greater tumor inhibition and reduced ocular tumor size relative to external blue light irradiation in the cited study.
Usefulness & Problems
Why this is useful
This harness is useful for nanoparticle-based optogenetic therapy in retinoblastoma because it enables in situ bioluminescence-driven light delivery rather than relying solely on external blue light irradiation. The cited study associates this design with improved therapeutic efficacy and significant reduction of ocular tumor size.
Source:
Herein, we present the demonstration of camouflage nanoparticle-based vectors for in situ bioluminescence-driven optogenetic therapy of retinoblastoma. To conduct proof-of-concept research, this study employs a mouse model of retinoblastoma.
Problem solved
It addresses the problem of delivering optogenetic therapy to retinoblastoma using a camouflage nanoparticle system that can operate through in situ bioluminescence. The evidence specifically frames the comparison against external blue light irradiation and reports superior tumor control for the developed system.
Source:
Herein, we present the demonstration of camouflage nanoparticle-based vectors for in situ bioluminescence-driven optogenetic therapy of retinoblastoma. To conduct proof-of-concept research, this study employs a mouse model of retinoblastoma.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A delivery strategy grouped with the mechanism branch because it determines how a system is instantiated and deployed in context.
Techniques
Structural CharacterizationTarget processes
No target processes tagged yet.
Input: Light
Implementation Constraints
The reported nanoparticle construct was camouflaged with folic acid ligands and luciferase NanoLuc-modified macrophage membranes. Beyond this composition and its use in in situ bioluminescence-driven optogenetic therapy, the supplied evidence does not specify expression system, substrate requirements, dosing, or manufacturing details.
The supplied evidence does not report detailed construct architecture, membrane preparation workflow, NanoLuc attachment strategy, or quantitative optical and pharmacological performance metrics. Validation is limited here to a single reported retinoblastoma application, with no independent replication provided in the evidence.
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Observations
successMouseapplication demomouse model of retinoblastoma
Inferred from claim c2 during normalization. Compared with external blue light irradiation, the developed system inhibited tumor growth with greater therapeutic efficacy and significantly reduced ocular tumor size. Derived from claim c2. Quoted text: In comparison to external blue light irradiation, the developed system enables an in situ bioluminescence-activated apoptotic pathway to inhibit tumor growth with greater therapeutic efficacy, resulting in a significant reduction in ocular tumor size.
Source:
ocular tumor size(significant_reduction)
successMouseapplication demomouse model of retinoblastomaretina
Inferred from claim c3 during normalization. Unlike external blue light irradiation, the camouflage nanoparticle-based optogenetic system maintained retinal structural integrity and avoided corneal neovascularization. Derived from claim c3. Quoted text: Furthermore, unlike external blue light irradiation, which causes retinal damage and corneal neovascularization, the camouflage nanoparticle-based optogenetic system maintains retinal structural integrity while avoiding corneal neovascularization.
Source:
successMouseapplication demomouse model of retinoblastoma
Inferred from claim c2 during normalization. Compared with external blue light irradiation, the developed system inhibited tumor growth with greater therapeutic efficacy and significantly reduced ocular tumor size. Derived from claim c2. Quoted text: In comparison to external blue light irradiation, the developed system enables an in situ bioluminescence-activated apoptotic pathway to inhibit tumor growth with greater therapeutic efficacy, resulting in a significant reduction in ocular tumor size.
Source:
ocular tumor size(significant_reduction)
successMouseapplication demomouse model of retinoblastomaretina
Inferred from claim c3 during normalization. Unlike external blue light irradiation, the camouflage nanoparticle-based optogenetic system maintained retinal structural integrity and avoided corneal neovascularization. Derived from claim c3. Quoted text: Furthermore, unlike external blue light irradiation, which causes retinal damage and corneal neovascularization, the camouflage nanoparticle-based optogenetic system maintains retinal structural integrity while avoiding corneal neovascularization.
Source:
successMouseapplication demomouse model of retinoblastoma
Inferred from claim c2 during normalization. Compared with external blue light irradiation, the developed system inhibited tumor growth with greater therapeutic efficacy and significantly reduced ocular tumor size. Derived from claim c2. Quoted text: In comparison to external blue light irradiation, the developed system enables an in situ bioluminescence-activated apoptotic pathway to inhibit tumor growth with greater therapeutic efficacy, resulting in a significant reduction in ocular tumor size.
Source:
ocular tumor size(significant_reduction)
successMouseapplication demomouse model of retinoblastomaretina
Inferred from claim c3 during normalization. Unlike external blue light irradiation, the camouflage nanoparticle-based optogenetic system maintained retinal structural integrity and avoided corneal neovascularization. Derived from claim c3. Quoted text: Furthermore, unlike external blue light irradiation, which causes retinal damage and corneal neovascularization, the camouflage nanoparticle-based optogenetic system maintains retinal structural integrity while avoiding corneal neovascularization.
Source:
successMouseapplication demomouse model of retinoblastoma
Inferred from claim c2 during normalization. Compared with external blue light irradiation, the developed system inhibited tumor growth with greater therapeutic efficacy and significantly reduced ocular tumor size. Derived from claim c2. Quoted text: In comparison to external blue light irradiation, the developed system enables an in situ bioluminescence-activated apoptotic pathway to inhibit tumor growth with greater therapeutic efficacy, resulting in a significant reduction in ocular tumor size.
Source:
ocular tumor size(significant_reduction)
successMouseapplication demomouse model of retinoblastomaretina
Inferred from claim c3 during normalization. Unlike external blue light irradiation, the camouflage nanoparticle-based optogenetic system maintained retinal structural integrity and avoided corneal neovascularization. Derived from claim c3. Quoted text: Furthermore, unlike external blue light irradiation, which causes retinal damage and corneal neovascularization, the camouflage nanoparticle-based optogenetic system maintains retinal structural integrity while avoiding corneal neovascularization.
Source:
successMouseapplication demomouse model of retinoblastoma
Inferred from claim c2 during normalization. Compared with external blue light irradiation, the developed system inhibited tumor growth with greater therapeutic efficacy and significantly reduced ocular tumor size. Derived from claim c2. Quoted text: In comparison to external blue light irradiation, the developed system enables an in situ bioluminescence-activated apoptotic pathway to inhibit tumor growth with greater therapeutic efficacy, resulting in a significant reduction in ocular tumor size.
Source:
ocular tumor size(significant_reduction)
successMouseapplication demomouse model of retinoblastomaretina
Inferred from claim c3 during normalization. Unlike external blue light irradiation, the camouflage nanoparticle-based optogenetic system maintained retinal structural integrity and avoided corneal neovascularization. Derived from claim c3. Quoted text: Furthermore, unlike external blue light irradiation, which causes retinal damage and corneal neovascularization, the camouflage nanoparticle-based optogenetic system maintains retinal structural integrity while avoiding corneal neovascularization.
Source:
successMouseapplication demomouse model of retinoblastoma
Inferred from claim c2 during normalization. Compared with external blue light irradiation, the developed system inhibited tumor growth with greater therapeutic efficacy and significantly reduced ocular tumor size. Derived from claim c2. Quoted text: In comparison to external blue light irradiation, the developed system enables an in situ bioluminescence-activated apoptotic pathway to inhibit tumor growth with greater therapeutic efficacy, resulting in a significant reduction in ocular tumor size.
Source:
ocular tumor size(significant_reduction)
successMouseapplication demomouse model of retinoblastomaretina
Inferred from claim c3 during normalization. Unlike external blue light irradiation, the camouflage nanoparticle-based optogenetic system maintained retinal structural integrity and avoided corneal neovascularization. Derived from claim c3. Quoted text: Furthermore, unlike external blue light irradiation, which causes retinal damage and corneal neovascularization, the camouflage nanoparticle-based optogenetic system maintains retinal structural integrity while avoiding corneal neovascularization.
Source:
successMouseapplication demomouse model of retinoblastoma
Inferred from claim c2 during normalization. Compared with external blue light irradiation, the developed system inhibited tumor growth with greater therapeutic efficacy and significantly reduced ocular tumor size. Derived from claim c2. Quoted text: In comparison to external blue light irradiation, the developed system enables an in situ bioluminescence-activated apoptotic pathway to inhibit tumor growth with greater therapeutic efficacy, resulting in a significant reduction in ocular tumor size.
Source:
ocular tumor size(significant_reduction)
successMouseapplication demomouse model of retinoblastomaretina
Inferred from claim c3 during normalization. Unlike external blue light irradiation, the camouflage nanoparticle-based optogenetic system maintained retinal structural integrity and avoided corneal neovascularization. Derived from claim c3. Quoted text: Furthermore, unlike external blue light irradiation, which causes retinal damage and corneal neovascularization, the camouflage nanoparticle-based optogenetic system maintains retinal structural integrity while avoiding corneal neovascularization.
Source:
Supporting Sources
Ranked Claims
Camouflage nanoparticle-based vectors were demonstrated for in situ bioluminescence-driven optogenetic therapy of retinoblastoma.
Herein, we present the demonstration of camouflage nanoparticle-based vectors for in situ bioluminescence-driven optogenetic therapy of retinoblastoma. To conduct proof-of-concept research, this study employs a mouse model of retinoblastoma.
Camouflage nanoparticle-based vectors were demonstrated for in situ bioluminescence-driven optogenetic therapy of retinoblastoma.
Herein, we present the demonstration of camouflage nanoparticle-based vectors for in situ bioluminescence-driven optogenetic therapy of retinoblastoma. To conduct proof-of-concept research, this study employs a mouse model of retinoblastoma.
Camouflage nanoparticle-based vectors were demonstrated for in situ bioluminescence-driven optogenetic therapy of retinoblastoma.
Herein, we present the demonstration of camouflage nanoparticle-based vectors for in situ bioluminescence-driven optogenetic therapy of retinoblastoma. To conduct proof-of-concept research, this study employs a mouse model of retinoblastoma.
Camouflage nanoparticle-based vectors were demonstrated for in situ bioluminescence-driven optogenetic therapy of retinoblastoma.
Herein, we present the demonstration of camouflage nanoparticle-based vectors for in situ bioluminescence-driven optogenetic therapy of retinoblastoma. To conduct proof-of-concept research, this study employs a mouse model of retinoblastoma.
Camouflage nanoparticle-based vectors were demonstrated for in situ bioluminescence-driven optogenetic therapy of retinoblastoma.
Herein, we present the demonstration of camouflage nanoparticle-based vectors for in situ bioluminescence-driven optogenetic therapy of retinoblastoma. To conduct proof-of-concept research, this study employs a mouse model of retinoblastoma.
Camouflage nanoparticle-based vectors were demonstrated for in situ bioluminescence-driven optogenetic therapy of retinoblastoma.
Herein, we present the demonstration of camouflage nanoparticle-based vectors for in situ bioluminescence-driven optogenetic therapy of retinoblastoma. To conduct proof-of-concept research, this study employs a mouse model of retinoblastoma.
Camouflage nanoparticle-based vectors were demonstrated for in situ bioluminescence-driven optogenetic therapy of retinoblastoma.
Herein, we present the demonstration of camouflage nanoparticle-based vectors for in situ bioluminescence-driven optogenetic therapy of retinoblastoma. To conduct proof-of-concept research, this study employs a mouse model of retinoblastoma.
Compared with external blue light irradiation, the developed system inhibited tumor growth with greater therapeutic efficacy and significantly reduced ocular tumor size.
In comparison to external blue light irradiation, the developed system enables an in situ bioluminescence-activated apoptotic pathway to inhibit tumor growth with greater therapeutic efficacy, resulting in a significant reduction in ocular tumor size.
ocular tumor size significant reduction
Compared with external blue light irradiation, the developed system inhibited tumor growth with greater therapeutic efficacy and significantly reduced ocular tumor size.
In comparison to external blue light irradiation, the developed system enables an in situ bioluminescence-activated apoptotic pathway to inhibit tumor growth with greater therapeutic efficacy, resulting in a significant reduction in ocular tumor size.
ocular tumor size significant reduction
Compared with external blue light irradiation, the developed system inhibited tumor growth with greater therapeutic efficacy and significantly reduced ocular tumor size.
In comparison to external blue light irradiation, the developed system enables an in situ bioluminescence-activated apoptotic pathway to inhibit tumor growth with greater therapeutic efficacy, resulting in a significant reduction in ocular tumor size.
ocular tumor size significant reduction
Compared with external blue light irradiation, the developed system inhibited tumor growth with greater therapeutic efficacy and significantly reduced ocular tumor size.
In comparison to external blue light irradiation, the developed system enables an in situ bioluminescence-activated apoptotic pathway to inhibit tumor growth with greater therapeutic efficacy, resulting in a significant reduction in ocular tumor size.
ocular tumor size significant reduction
Compared with external blue light irradiation, the developed system inhibited tumor growth with greater therapeutic efficacy and significantly reduced ocular tumor size.
In comparison to external blue light irradiation, the developed system enables an in situ bioluminescence-activated apoptotic pathway to inhibit tumor growth with greater therapeutic efficacy, resulting in a significant reduction in ocular tumor size.
ocular tumor size significant reduction
Compared with external blue light irradiation, the developed system inhibited tumor growth with greater therapeutic efficacy and significantly reduced ocular tumor size.
In comparison to external blue light irradiation, the developed system enables an in situ bioluminescence-activated apoptotic pathway to inhibit tumor growth with greater therapeutic efficacy, resulting in a significant reduction in ocular tumor size.
ocular tumor size significant reduction
Compared with external blue light irradiation, the developed system inhibited tumor growth with greater therapeutic efficacy and significantly reduced ocular tumor size.
In comparison to external blue light irradiation, the developed system enables an in situ bioluminescence-activated apoptotic pathway to inhibit tumor growth with greater therapeutic efficacy, resulting in a significant reduction in ocular tumor size.
ocular tumor size significant reduction
Unlike external blue light irradiation, the camouflage nanoparticle-based optogenetic system maintained retinal structural integrity and avoided corneal neovascularization.
Furthermore, unlike external blue light irradiation, which causes retinal damage and corneal neovascularization, the camouflage nanoparticle-based optogenetic system maintains retinal structural integrity while avoiding corneal neovascularization.
Unlike external blue light irradiation, the camouflage nanoparticle-based optogenetic system maintained retinal structural integrity and avoided corneal neovascularization.
Furthermore, unlike external blue light irradiation, which causes retinal damage and corneal neovascularization, the camouflage nanoparticle-based optogenetic system maintains retinal structural integrity while avoiding corneal neovascularization.
Unlike external blue light irradiation, the camouflage nanoparticle-based optogenetic system maintained retinal structural integrity and avoided corneal neovascularization.
Furthermore, unlike external blue light irradiation, which causes retinal damage and corneal neovascularization, the camouflage nanoparticle-based optogenetic system maintains retinal structural integrity while avoiding corneal neovascularization.
Unlike external blue light irradiation, the camouflage nanoparticle-based optogenetic system maintained retinal structural integrity and avoided corneal neovascularization.
Furthermore, unlike external blue light irradiation, which causes retinal damage and corneal neovascularization, the camouflage nanoparticle-based optogenetic system maintains retinal structural integrity while avoiding corneal neovascularization.
Unlike external blue light irradiation, the camouflage nanoparticle-based optogenetic system maintained retinal structural integrity and avoided corneal neovascularization.
Furthermore, unlike external blue light irradiation, which causes retinal damage and corneal neovascularization, the camouflage nanoparticle-based optogenetic system maintains retinal structural integrity while avoiding corneal neovascularization.
Unlike external blue light irradiation, the camouflage nanoparticle-based optogenetic system maintained retinal structural integrity and avoided corneal neovascularization.
Furthermore, unlike external blue light irradiation, which causes retinal damage and corneal neovascularization, the camouflage nanoparticle-based optogenetic system maintains retinal structural integrity while avoiding corneal neovascularization.
Unlike external blue light irradiation, the camouflage nanoparticle-based optogenetic system maintained retinal structural integrity and avoided corneal neovascularization.
Furthermore, unlike external blue light irradiation, which causes retinal damage and corneal neovascularization, the camouflage nanoparticle-based optogenetic system maintains retinal structural integrity while avoiding corneal neovascularization.
Approval Evidence
1 source3 linked approval claimsfirst-pass slug nanoluc-modified-macrophage-membranes
camouflaged with folic acid ligands and luciferase NanoLuc-modified macrophage membranes
Source:
application demonstrationsupports
Camouflage nanoparticle-based vectors were demonstrated for in situ bioluminescence-driven optogenetic therapy of retinoblastoma.
Herein, we present the demonstration of camouflage nanoparticle-based vectors for in situ bioluminescence-driven optogenetic therapy of retinoblastoma. To conduct proof-of-concept research, this study employs a mouse model of retinoblastoma.
Source:
comparative efficacysupports
Compared with external blue light irradiation, the developed system inhibited tumor growth with greater therapeutic efficacy and significantly reduced ocular tumor size.
In comparison to external blue light irradiation, the developed system enables an in situ bioluminescence-activated apoptotic pathway to inhibit tumor growth with greater therapeutic efficacy, resulting in a significant reduction in ocular tumor size.
Source:
safety comparisonsupports
Unlike external blue light irradiation, the camouflage nanoparticle-based optogenetic system maintained retinal structural integrity and avoided corneal neovascularization.
Furthermore, unlike external blue light irradiation, which causes retinal damage and corneal neovascularization, the camouflage nanoparticle-based optogenetic system maintains retinal structural integrity while avoiding corneal neovascularization.
Source:
Comparisons
Source-backed strengths
The main reported strength is application-level efficacy in a retinoblastoma setting, where camouflage nanoparticles enabled in situ bioluminescence-driven optogenetic therapy. In the cited comparison, the system inhibited tumor growth more effectively than external blue light irradiation and significantly reduced ocular tumor size.
Source:
In comparison to external blue light irradiation, the developed system enables an in situ bioluminescence-activated apoptotic pathway to inhibit tumor growth with greater therapeutic efficacy, resulting in a significant reduction in ocular tumor size.
Ranked Citations
- 1.